Clostridium Difficile News and Research RSS Feed - Clostridium Difficile News and Research

Clostridium difficile is a type of bacterium found in human and animal waste. Clostridium difficile is a common cause of diarrhea that occurs in hospitals. It can also cause diarrhea or other intestinal disorders in patients treated with antibiotics.
IPs spend more time in collecting and reporting hospital infection data than protecting patients

IPs spend more time in collecting and reporting hospital infection data than protecting patients

Collecting and reporting hospital infection data to federal health agencies takes more than 5 hours each day, at the expense of time needed to ensure that frontline healthcare personnel are adhering to basic infection prevention practices such as hand hygiene, according to a recent case study, to be presented on Saturday, June 27 at the 42nd Annual Conference of the Association for Professionals in Infection Control and Epidemiology. [More]
Stable IV formulation to treat systemic susceptible and resistant Gram-positive hospital-acquired infections

Stable IV formulation to treat systemic susceptible and resistant Gram-positive hospital-acquired infections

MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, to address the major global problem of antibiotic resistance - announces that it has developed a stable intravenous (IV) formulation of MGB-BP-3, designed for the treatment of systemic susceptible and resistant Gram-positive hospital-acquired infections. [More]
Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration for Xifaxan 550 mg for the treatment of IBS-D in adults. [More]
Roche announces FDA clearance for cobas Cdiff Test to detect C. difficile in stool specimens

Roche announces FDA clearance for cobas Cdiff Test to detect C. difficile in stool specimens

Roche announced today that the US Food and Drug Administration has provided 510(k) clearance for the cobas Cdiff Test to detect Clostridium difficile (C. difficile) in stool specimens. [More]
CSGI joins with two California hospitals to eradicate deadly Clostridium difficile infections

CSGI joins with two California hospitals to eradicate deadly Clostridium difficile infections

Clean Sweep Group Inc., a Beverly Hills, CA, based microbial disinfection service company, joins with two California hospitals to significantly reduce deadly Clostridium difficile infections caught in their hospitals using ultraviolet (UV-C) germ-killing advanced disinfection devices. [More]
Treatment significantly reduces risk of CDI recurrence

Treatment significantly reduces risk of CDI recurrence

Among patients with Clostridium difficile infection (CDI) who recovered following standard treatment with the antibiotics metronidazole or vancomycin, oral administration of spores of a strain of C difficile that does not produce toxins colonized the gastrointestinal tract and significantly reduced CDI recurrence, according to a study in the May 5 issue of JAMA. [More]
Fecal transplantation cures C. diff infection, eliminates multi-drug resistant pathogens

Fecal transplantation cures C. diff infection, eliminates multi-drug resistant pathogens

A fecal microbiota transplant (FMT) not only cured a case of Clostridium difficile (C. diff) infection in a 66 year old man; it eliminated populations of multi-drug resistant organisms both in the patient's gastrointestinal tract, and several other body sites. [More]
Luminex provides clinical trial update on ARIES HSV 1&2 Assay

Luminex provides clinical trial update on ARIES HSV 1&2 Assay

Luminex Corporation today announced that testing at the clinical trial sites for the ARIES HSV 1&2 Assay is now complete. The next steps, including site to site reproducibility testing, followed by data analysis and assembly of the data package for submission to the FDA, are now underway. [More]
TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, today announced the presentation of data demonstrating the promise of its lead clinical candidate, TXA709, in combating antibiotic resistance. [More]
U-M study: Nearly half of American hospitals not taking key steps to prevent C. diff infections

U-M study: Nearly half of American hospitals not taking key steps to prevent C. diff infections

Nearly half of American hospitals aren't taking key steps to prevent a kind of gut infection that kills nearly 30,000 people annually and sickens hundreds of thousands more - despite strong evidence that such steps work, according to a new study. [More]
Focus Diagnostics announces FDA clearance for Simplexa Group A Strep Direct Kit

Focus Diagnostics announces FDA clearance for Simplexa Group A Strep Direct Kit

Focus Diagnostics, the clinical-laboratory products business of Quest Diagnostics, today announced the FDA 510(k) clearance and CLIA moderate-complexity categorization for its Simplexa Group A Strep Direct Kit. Simplexa Group A Strep Direct is a real-time polymerase chain reaction assay for the detection of Group A Streptococcus bacteria directly from throat swabs. [More]
Infectious diseases experts release new guidance to avoid infections during hospital visits

Infectious diseases experts release new guidance to avoid infections during hospital visits

Leading infectious diseases experts have released new guidance for healthcare facilities looking to establish precautions for visitors of patients with infectious diseases. The guidance looks to reduce the potential for healthcare visitors in spreading dangerous bacteria within the healthcare facility and community. [More]
Fecal microbiota transplantation more successful for treating Clostridium difficile infections

Fecal microbiota transplantation more successful for treating Clostridium difficile infections

Distasteful though it sounds, the transplantation of fecal matter is more successful for treating Clostridium difficile infections than previously thought. [More]
Study finds C. difficile infection increases hospital readmission rates

Study finds C. difficile infection increases hospital readmission rates

Patients with Clostridium difficile infection (CDI) are twice as likely to be readmitted to the hospital as patients without the deadly diarrheal infection, according to a study published in the April issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology. [More]
Aggressive campaign to cut unnecessary use of antibiotics helps reduce drug-resistant bacteria

Aggressive campaign to cut unnecessary use of antibiotics helps reduce drug-resistant bacteria

An aggressive campaign to reduce the unnecessary use of antibiotics has helped cut the rate of infection with a dangerous drug-resistant bacteria at The Valley Hospital by nearly 40 percent. [More]

Deadly C. difficile affected almost half a million in the U.S over one year

The deadly bug Clostridium difficile (C. diff) infected more than 450,000 people in the U.S in a single year, according to new research funded by the Centers for Disease Control and Prevention (CDC). [More]
Researchers reveal how C. difficile wreaks havoc on guts, causes life-threatening diseases

Researchers reveal how C. difficile wreaks havoc on guts, causes life-threatening diseases

In a new paper in the journal Infection and Immunity, the researchers lay out for the first time exactly how C. difficile wreaks havoc on the guts of animals in a short time, and causes severe diarrhea and life-threatening disease in humans. [More]
Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy. [More]
Risks and benefits of fecal microbiota transplant

Risks and benefits of fecal microbiota transplant

A woman successfully treated for a recurrent Clostridium difficile infection with stool from an overweight donor rapidly gained weight herself afterwards, becoming obese, according to a case report published in the new journal Open Forum Infectious Diseases. [More]
Bathing critically ill patients with chlorhexidine wipes does not prevent ICU infections

Bathing critically ill patients with chlorhexidine wipes does not prevent ICU infections

Vanderbilt University Medical Center researchers have found that bathing critically ill patients with disposable chlorhexidine cloths did not decrease the incidence of health care-associated infections when compared to less expensive nonantimicrobial cloths, according to a study appearing online in JAMA this week. [More]
Advertisement
Advertisement